Standing with Louisiana women and families affected by defective and dangerous breast implants.
Understanding the Allergan Breast Implant Recall
The FDA and international health agencies identified a strong correlation between Allergan’s textured implant surface and the development of BIA-ALCL, a rare form of non-Hodgkin’s lymphoma. Key findings include:
- 573+ reported BIA-ALCL cases worldwide, according to FDA records
- 84% of all cases involve Allergan or subsidiary implants (Inamed, McGhan)
- Implants were banned in Europe in 2018
- The FDA ordered a U.S. recall in July 2019
- Dozens of associated deaths have been reported
- Cancer may appear 6 months to 26 years after implantation
While research continues, evidence strongly suggests Allergan’s BIOCELL® textured surface poses an elevated cancer risk, and many women were never properly warned.
